Originally published as JCO Early Release 10.1200/JCO.2006.06.4642 on October 10 2006
Journal of Clinical Oncology, Vol 24, No 31 (November 1), 2006: pp. 5052-5059
© 2006 American Society of Clinical Oncology.
Number of CD4+ Cells and Location of Forkhead Box Protein P3–Positive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome
Abigail M. Lee,
Andrew J. Clear,
Maria Calaminici,
Andrew J. Davies,
Suzanne Jordan,
Finlay MacDougall,
Janet Matthews,
Andrew J. Norton,
John G. Gribben,
T. Andrew Lister,
Lindsey K. Goff
From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, Charterhouse Square; and Department of Histopathology, St Bartholomew's Hospital, West Smithfield, London, United Kingdom
Address reprint requests to Lindsey Goff, PhD, Cancer Research UK, Medical Oncology Unit, 3rd Floor, John Vane Science Building, Charterhouse Square, London EC1M 6BQ, United Kingdom; e-mail: lindsey.goff{at}cancer.org.uk
Purpose To examine the immune microenvironment in diagnostic follicular lymphoma (FL) biopsies and evaluate its prognostic significance.
Patients and Methods Immunohistochemistry was used to study numbers and location of cells staining positive for immune cell markers CD4, CD7, CD8, CD25, CD68, forkhead box protein P3 (FOXP3), T-cell intracellular antigen-1, and Granzyme B in tissue microarrays of paraffin-embedded, diagnostic lymph node biopsies taken from 59 FL patients who lived less than 5 years (short-survival group; n = 34) and more than 15 years (long-survival group; n = 25).
Results CD4 and FOXP3 expression were significantly different between the two groups. Samples from the long-survival group were more likely than those from the short-survival group to have CD4+ staining cells and to have FOXP3-positive cells in a perifollicular location.
Conclusion This study has identified differences in immune cell composition of the diagnostic FL lymph node immune microenvironment and these have the potential for use as prognostic biomarkers in a routine histopathology setting.
published online ahead of print at www.jco.org on October 10, 2006.
Supported in part by Cancer Research UK, the Research Advisory Board of St Bartholomew's Hospital, the Royal London Charitable Foundation (Grant No. RAB03/PJ/07), and Kay Kendall Leukaemia Fund.
Presented at American Society of Hematology, Atlanta, GA, December 10-13, 2005.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. G. Ramsay, A. J. Clear, G. Kelly, R. Fatah, J. Matthews, F. MacDougall, T. A. Lister, A. M. Lee, M. Calaminici, and J. G. Gribben
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
Blood,
November 19, 2009;
114(21):
4713 - 4720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Sweetenham, B. Goldman, M. L. LeBlanc, J. R. Cook, R. R. Tubbs, O. W. Press, D. G. Maloney, R. I. Fisher, L. M. Rimsza, R. M. Braziel, et al.
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study
Ann. Onc.,
October 29, 2009;
(2009)
mdp460v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Burger, P. Ghia, A. Rosenwald, and F. Caligaris-Cappio
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Blood,
October 15, 2009;
114(16):
3367 - 3375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Badoual, S. Hans, W. H. Fridman, D. Brasnu, S. Erdman, and E. Tartour
Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer
J. Clin. Oncol.,
July 1, 2009;
27(19):
e5 - e6.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Carreras, A. Lopez-Guillermo, G. Roncador, N. Villamor, L. Colomo, A. Martinez, R. Hamoudi, W. J. Howat, E. Montserrat, and E. Campo
High Numbers of Tumor-Infiltrating Programmed Cell Death 1-Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma
J. Clin. Oncol.,
March 20, 2009;
27(9):
1470 - 1476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lejeune and T. Alvaro
Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma
Haematologica,
January 1, 2009;
94(1):
16 - 21.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. de Jong, A. Koster, A. Hagenbeek, J. Raemaekers, D. Veldhuizen, S. Heisterkamp, J. P. de Boer, and M. van Glabbeke
Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols
Haematologica,
January 1, 2009;
94(1):
70 - 77.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ott and A. Rosenwald
Molecular pathogenesis of follicular lymphoma
Haematologica,
December 1, 2008;
93(12):
1773 - 1776.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin,
September 1, 2008;
58(5):
305 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Proto-Siqueira, R. A. Panepucci, F. P. Careta, A. Lee, A. Clear, K. Morris, C. Owen, E. G. Rizzatti, W. A. Silva Jr, R. P. Falcao, et al.
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL
Blood,
July 15, 2008;
112(2):
394 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A. Johnson and R. D. Gascoyne
Gene expression signatures in follicular lymphoma: are they ready for the clinic?
Haematologica,
July 1, 2008;
93(7):
982 - 987.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Piccaluga, A. Califano, U. Klein, C. Agostinelli, B. Bellosillo, E. Gimeno, S. Serrano, F. Sole, Y. Zang, B. Falini, et al.
Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
Haematologica,
July 1, 2008;
93(7):
1033 - 1038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. M. Patten, A. G. S. Buggins, J. Richards, A. Wotherspoon, J. Salisbury, G. J. Mufti, T. J. Hamblin, and S. Devereux
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment
Blood,
May 15, 2008;
111(10):
5173 - 5181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Byers, E. Sakhinia, P. Joseph, C. Glennie, J. A. Hoyland, L. P. Menasce, J. A. Radford, and T. Illidge
Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling
Blood,
May 1, 2008;
111(9):
4764 - 4770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Taskinen, M.-L. Karjalainen-Lindsberg, and S. Leppa
Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP
Blood,
May 1, 2008;
111(9):
4664 - 4667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tzankov, C. Meier, P. Hirschmann, P. Went, S. A. Pileri, and S. Dirnhofer
Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma
Haematologica,
February 1, 2008;
93(2):
193 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Canioni, G. Salles, N. Mounier, N. Brousse, M. Keuppens, F. Morchhauser, T. Lamy, A. Sonet, M.-C. Rousselet, C. Foussard, et al.
High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial
J. Clin. Oncol.,
January 20, 2008;
26(3):
440 - 446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H. Schreiber
The Use of FoxP3 as a Biomarker and Prognostic Factor for Malignant Human Tumors
Cancer Epidemiol. Biomarkers Prev.,
October 1, 2007;
16(10):
1931 - 1934.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Taskinen, M.-L. Karjalainen-Lindsberg, H. Nyman, L.-M. Eerola, and S. Leppa
A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone
Clin. Cancer Res.,
October 1, 2007;
13(19):
5784 - 5789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Ross, P. D. Ouillette, C. M. Saddler, K. A. Shedden, and S. N. Malek
Comprehensive Analysis of Copy Number and Allele Status Identifies Multiple Chromosome Defects Underlying Follicular Lymphoma Pathogenesis
Clin. Cancer Res.,
August 15, 2007;
13(16):
4777 - 4785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Klapper, E. Hoster, L. Rolver, C. Schrader, D. Janssen, M. Tiemann, H.-W. Bernd, O. Determann, M.-L. Hansmann, P. Moller, et al.
Tumor Sclerosis but Not Cell Proliferation or Malignancy Grade Is a Prognostic Marker in Advanced-Stage Follicular Lymphoma: The German Low Grade Lymphoma Study Group
J. Clin. Oncol.,
August 1, 2007;
25(22):
3330 - 3336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Strauss, C. Bergmann, M. Szczepanski, W. Gooding, J. T. Johnson, and T. L. Whiteside
A Unique Subset of CD4+CD25highFoxp3+ T Cells Secreting Interleukin-10 and Transforming Growth Factor-{beta}1 Mediates Suppression in the Tumor Microenvironment
Clin. Cancer Res.,
August 1, 2007;
13(15):
4345 - 4354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Gao, S.-J. Qiu, J. Fan, J. Zhou, X.-Y. Wang, Y.-S. Xiao, Y. Xu, Y.-W. Li, and Z.-Y. Tang
Intratumoral Balance of Regulatory and Cytotoxic T Cells Is Associated With Prognosis of Hepatocellular Carcinoma After Resection
J. Clin. Oncol.,
June 20, 2007;
25(18):
2586 - 2593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology,
January 1, 2007;
2007(1):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
